This study first established the optimal treatment duration and multiplicity of infection (MOI) for Brucella suis vaccine strain S2 (B. suis S2) to inhibit the IRE1/caspase-12/caspase-3 pathway in human microglial clone 3 (HMC3) cells. Here, CASP12 is linked to infection.